Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in PNH patients switching from anti-C5 therapy
NCT05630001Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Started Apr 2023; status: completed.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05630001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630001.